Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029
전 세계 올리고뉴클레오티드 CDMO 시장 규모는 2024년 25억 1,000만 달러에서 2029년에는 67억 3,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 21.8%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.
시장 성장을 가속하는 주요 요인으로는 신규 올리고 기반 의약품 출시에 대한 관심 증가, CDMO에 대한 아웃소싱 확대 등을 꼽을 수 있습니다. 안티센스 올리고뉴클레오티드(ASO), 저분자 간섭 RNA(siRNA), 압타머와 같은 올리고뉴클레오티드는 이러한 약물이 제공하는 특이성과 표적 작용으로 인해 주목을 받고 있습니다. 이 때문에 개발 활동이 활발해지면서 FDA의 승인이 잇따르고 있습니다. 예를 들어, 2023년 4월, Qalsody(tofersen)는 슈퍼옥사이드 디스뮤타제1(SOD1) 유전자 돌연변이와 관련된 근위축성 측색경화증(ALS) 치료제로 미국 FDA의 승인을 받았습니다. 또한, 임상 개발 및 제조(임상 및 상업)를 아웃소싱할 때 발생하는 전문성과 저렴한 비용으로 인해 이 시장의 성장이 더욱 가속화되고 있습니다.
| 조사 범위 |
| 조사 대상연도 |
2022-2029년 |
| 기준연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(미화) |
| 부문별 |
서비스 유형별, 유형별, 용도별, 최종사용자별, 지역별로 구분 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카 |
2023년 위탁생산 부문이 올리고뉴클레오티드 CDMO 시장에서 가장 큰 점유율을 차지했습니다. 올리고뉴클레오타이드 치료제에 대한 수요 증가와 CDMO가 제공하는 전문 지식이 생산 기간 단축 및 생산 확장성 향상으로 이어지는 등의 요인이 이 부문의 성장을 뒷받침하고 있습니다. 또한, CDMO가 제공하는 규제 관련 전문 지식은 시장 출시 기간과 운영상의 위험을 더욱 줄여 CDMO에 대한 제조 위탁을 촉진하는 또 다른 요인으로 작용하고 있습니다.
제약 및 생명공학 기업은 올리고뉴클레오티드 CDMO 시장의 주요 최종 사용자 분야입니다. 올리고 기반 치료제에 대한 임상 및 상업적 수요가 증가함에 따라 제약 및 생명공학 기업들이 CDMO에 생산을 위탁하는 원동력이 되고 있습니다. 올리고뉴클레오타이드 합성은 복잡하고 전문 지식, 첨단 기술 및 규제 준수가 필요하며, CDMO는 이러한 기업들에게 이를 제공할 수 있는 인프라와 시스템을 갖추고 있습니다. 따라서 제약 및 생명 공학 회사는 주로 제조, 충전 마감 및 기타 서비스를 CDMO에 의존하고 있습니다.
중국, 인도, 일본, 한국 등 아시아태평양은 올리고뉴클레오티드 기반 의약품과 같은 혁신적인 치료법에 대한 관심이 높아지면서 바이오 의약품 산업이 빠르게 성장하고 있습니다. 또한 아태지역은 인건비, 생산비, 운영비가 낮아 CDMO 서비스 비용 측면에서 큰 이점을 가지고 있습니다. 이 때문에 세계 기업들은 아태지역에서 제조 업무를 아웃소싱하는 것에 매력을 느끼고 있습니다.
이 보고서는 세계의 올리고뉴클레오타이드 CDMO 시장을 조사했으며, 서비스 유형별/유형별/용도별/최종 사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리한 보고서입니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 공급망 분석
- 밸류체인 분석
- 생태계 분석
- 기술 분석
- 가격 분석
- 2024-2025년 주요 컨퍼런스 및 이벤트
- 규제 상황
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 주요 구입 기준
- 투자와 자금조달 시나리오
- AI/생성형 AI가 올리고뉴클레오티드 CDMO 시장에 미치는 영향
제6장 올리고뉴클레오티드 CDMO 시장, 서비스 유형별
제7장 올리고뉴클레오티드 CDMO 시장, 유형별
- 서론
- 안티센스 올리고뉴클레오티드
- 저분자 간섭 RNA
- 기타
제8장 올리고뉴클레오티드 CDMO 시장, 용도별
제9장 올리고뉴클레오티드 CDMO 시장, 최종사용자별
- 서론
- 제약 기업 및 바이오테크놀러지 기업
- 진단 기업
- 기타
제10장 올리고뉴클레오티드 CDMO 시장, 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 헬스케어에 대한 투자 증가와 맞춤형 의료에 대한 주목 증가가 시장 성장을 촉진
- 중동의 거시경제 전망
- 아프리카 거시경제 전망
제11장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점
- 매출 분석, 2021년-2023년
- 시장 점유율 분석, 2023년
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 가치 평가와 재무 지표
- 브랜드/서비스 비교
- 경쟁 시나리오
제12장 기업 개요
- 주요 시장 진출기업
- BACHEM
- THERMO FISHER SCIENTIFIC INC.
- AGILENT TECHNOLOGIES, INC.
- WUXI APPTEC
- MARAVAI LIFESCIENCES
- LONZA
- EUROFINS SCIENTIFIC
- DANAHER CORPORATION
- GENSCRIPT
- SYNGENE INTERNATIONAL LIMITED
- EUROAPI
- AJINOMOTO CO., INC.
- ST PHARM
- KANEKA CORPORATION
- POLYPEPTIDE GROUP
- AURIGENE PHARMACEUTICAL SERVICES LTD.
- BIOSPRING
- 기타 기업
- OLIGO FACTORY
- CORDEN PHARMA
- LGC BIOSEARCH TECHNOLOGIES
- BI0-SYNTHESIS, INC.
- MICROSYNTH
- SYNOLIGO BIOTECHNOLOGIES, INC.
- HONGENE BIOTECH CORPORATION
- SYLENTIS, S.A.
- CREATIVE BIOGENE
제13장 부록
LSH
The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs. Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Service type, Type, Application, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023"
In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.
"The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period"
Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.
"Asia Pacific: The fastest growing region in the oligonucleotide CDMO market"
Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Supply Side - 65% and Demand Side - 35%
- By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa - 5%
List of Companies Profiled in the Report:
- Bachem (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Maravai Lifesciences (US)
- GenScript (US)
- Wuxi Apptec (China)
- Eurofins Scientific (Luxembourg)
- Lonza (Switzerland)
- Danaher Corporation (US)
- Syngene International Limited (US)
- EUROAPI (France)
- Ajinomoto Co., Inc. (Japan)
- ST Pharm (South Korea)
- Kaneka Corporation (Japan)
- Aurigene Pharmaceutical Services Ltd. (India)
- PolyPeptide Group (Switzerland)
- Biospring (Germany)
- Oligo factory (US)
- Corden Pharma (Switzerland)
- LGC Biosearch Technologies (UK)
- Bio-Synthesis Inc (US)
- Microsynth (Switzerland)
- Synoligo Biotechnologies, Inc. (US)
- Hongene Biotech Corporation (China)
- Sylentis, S.A. (Spain)
- Creative Biogene. (US)
Research Coverage:
This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing ), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
- Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
- Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide CDMO market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED & REGIONS CONSIDERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.2 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
- 4.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE & COUNTRY (2023)
- 4.3 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS 2029
- 4.4 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS 2029
- 4.5 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY END USER, 2023
- 4.6 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing focus on development and commercialization of oligo-based therapeutics
- 5.2.1.2 Advantages of contract development and manufacturing
- 5.2.1.3 Increasing focus on precision/personalized medicine
- 5.2.1.4 Technological advancements
- 5.2.2 RESTRAINTS
- 5.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
- 5.2.4 CHALLENGES
- 5.2.4.1 Lack of sustainable and eco-friendly supply chain
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 ECOSYSTEM ANALYSIS
- 5.7 TECHNOLOGY ANALYSIS
- 5.7.1 KEY TECHNOLOGIES
- 5.7.1.1 Process technologies
- 5.7.1.1.1 Solid-phase synthesis
- 5.7.1.1.2 Liquid-phase synthesis
- 5.7.1.1.3 Enzymatic oligo synthesis
- 5.7.2 COMPLEMENTARY TECHNOLOGIES
- 5.7.2.1 Purification, analysis, and quality control technologies
- 5.7.2.1.1 Chromatography
- 5.7.2.1.2 Mass spectrometry
- 5.7.2.2 Other technologies
- 5.7.2.2.1 Polymerase chain reaction (PCR)
- 5.7.2.2.2 Next-generation sequencing
- 5.7.3 ADJACENT TECHNOLOGIES
- 5.8 PRICING ANALYSIS
- 5.8.1 INDICATIVE PRICE OF OLIGONUCLEOTIDE CDMO SERVICES, BY KEY PLAYER
- 5.8.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE)
- 5.9 KEY CONFERENCES & EVENTS IN 2024-2025
- 5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10.2 REGULATORY FRAMEWORK
- 5.11 PORTER'S FIVE FORCES ANALYSIS
- 5.11.1 DEGREE OF COMPETITION
- 5.11.2 BARGAINING POWER OF SUPPLIERS
- 5.11.3 BARGAINING POWER OF BUYERS
- 5.11.4 THREAT OF SUBSTITUTES
- 5.11.5 THREAT OF NEW ENTRANTS
- 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.12.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE CDMO SERVICES
- 5.13 KEY BUYING CRITERIA
- 5.14 INVESTMENT & FUNDING SCENARIO
- 5.15 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
6 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE
- 6.1 INTRODUCTION
- 6.2 CONTRACT MANUFACTURING
- 6.2.1 COMMERCIAL STAGE
- 6.2.1.1 Flexible, scalable production facilities to propel market growth
- 6.2.2 CLINICAL STAGE
- 6.2.2.1 Growing demand for oligonucleotide-based therapeutics to drive market
- 6.3 CONTRACT DEVELOPMENT
- 6.3.1 GROWING FOCUS ON REDUCING MANUFACTURING RISKS TO SUPPORT MARKET GROWTH
- 6.4 OTHER SERVICES
7 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.2 ANTISENSE OLIGONUCLEOTIDES
- 7.2.1 SPECIFIC DEVELOPMENT & MANUFACTURING REQUIREMENTS WELL-SUPPORTED BY CDMOS TO DRIVE MARKET GROWTH
- 7.3 SMALL INTERFERING RNA
- 7.3.1 POTENTIAL IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
- 7.4 OTHER OLIGONUCLEOTIDES
8 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 THERAPEUTIC APPLICATIONS
- 8.2.1 GROWING DEMAND FOR OLIGONUCLEOTIDE-BASED THERAPEUTICS TO DRIVE MARKET GROWTH
- 8.3 RESEARCH APPLICATIONS
- 8.3.1 USE OF OLIGOS IN SEQUENCING FOR ADVANCING DRUG DEVELOPMENT TO SUPPORT GROWTH
- 8.4 DIAGNOSTIC APPLICATIONS
- 8.4.1 GROWING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND IVD TO PROPEL MARKET
9 OLIGONUCLEOTIDE CDMO MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 INCREASED INVESTMENTS IN OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT MARKET GROWTH
- 9.3 DIAGNOSTIC COMPANIES
- 9.3.1 GROWTH OF PERSONALIZED DIAGNOSTICS TO PROPEL MARKET
- 9.4 OTHER END USERS
10 OLIGONUCLEOTIDE CDMO MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 10.2.2 US
- 10.2.2.1 Rising approvals of oligonucleotide-based drugs to support market growth
- 10.2.3 CANADA
- 10.2.3.1 Government initiatives to drive market growth in Canada
- 10.3 EUROPE
- 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 10.3.2 GERMANY
- 10.3.2.1 Academic-industry collaborations to drive market
- 10.3.3 UK
- 10.3.3.1 Strategic investments in biomanufacturing to boost market growth
- 10.3.4 FRANCE
- 10.3.4.1 Focus on advanced biologics manufacturing to drive market
- 10.3.5 ITALY
- 10.3.5.1 Increasing focus on biotechnology innovation to boost market growth
- 10.3.6 SPAIN
- 10.3.6.1 Strategic investments in biotechnology to support market growth
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 10.4.2 CHINA
- 10.4.2.1 Government-backed Initiatives and expansion of major companies to strengthen biotechnology sector in China
- 10.4.3 JAPAN
- 10.4.3.1 Increased investment in oligonucleotide research and manufacturing to boost market
- 10.4.4 INDIA
- 10.4.4.1 Rapidly expanding biopharma ecosystem to drive market
- 10.4.5 SOUTH KOREA
- 10.4.5.1 Robust government support to expand oligonucleotide CDMO sector
- 10.4.6 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 10.5.2 BRAZIL
- 10.5.2.1 Strong research institutions and growing collaboration between academia and industry to support market growth
- 10.5.3 MEXICO
- 10.5.3.1 Rapidly advancing pharmaceutical and biotechnology sectors to fuel growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 RISING INVESTMENTS IN HEALTHCARE AND GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET
- 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 10.6.3 MACROECONOMIC OUTLOOK FOR AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET
- 11.3 REVENUE ANALYSIS, 2021-2023
- 11.4 MARKET SHARE ANALYSIS, 2023
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 11.5.5.1 Company footprint
- 11.5.5.2 Region footprint
- 11.5.5.3 Service type footprint
- 11.5.5.4 Type footprint
- 11.5.5.5 Application footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING
- 11.6.5.1 Detailed list of key startups/SMES
- 11.6.5.2 Competitive benchmarking of startups/SMEs
- 11.7 COMPANY VALUATION AND FINANCIAL METRICS
- 11.8 BRAND/SERVICE COMPARISON
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 DEALS
- 11.9.2 EXPANSIONS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 BACHEM
- 12.1.1.1 Business overview
- 12.1.1.2 Services offered
- 12.1.1.3 Recent developments
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 THERMO FISHER SCIENTIFIC INC.
- 12.1.2.1 Business overview
- 12.1.2.2 Services offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Deals
- 12.1.2.3.2 Expansions
- 12.1.2.4 MnM view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 AGILENT TECHNOLOGIES, INC.
- 12.1.3.1 Business overview
- 12.1.3.2 Services offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Deals
- 12.1.3.3.2 Expansions
- 12.1.3.4 MnM view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 WUXI APPTEC
- 12.1.4.1 Business overview
- 12.1.4.2 Services offered
- 12.1.4.3 Recent developments
- 12.1.4.4 MnM view
- 12.1.4.4.1 Key strengths
- 12.1.4.4.2 Strategic choices made
- 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 MARAVAI LIFESCIENCES
- 12.1.5.1 Business overview
- 12.1.5.2 Services offered
- 12.1.5.3 Recent developments
- 12.1.6 LONZA
- 12.1.6.1 Business overview
- 12.1.6.2 Services offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Deals
- 12.1.6.3.2 Expansions
- 12.1.7 EUROFINS SCIENTIFIC
- 12.1.7.1 Business overview
- 12.1.7.2 Services offered
- 12.1.7.3 Recent developments
- 12.1.7.3.1 Deals
- 12.1.7.3.2 Expansions
- 12.1.8 DANAHER CORPORATION
- 12.1.8.1 Business overview
- 12.1.8.2 Services offered
- 12.1.8.3 Recent developments
- 12.1.9 GENSCRIPT
- 12.1.9.1 Business overview
- 12.1.9.2 Services offered
- 12.1.9.3 Recent developments
- 12.1.10 SYNGENE INTERNATIONAL LIMITED
- 12.1.10.1 Business overview
- 12.1.10.2 Services offered
- 12.1.10.3 Recent developments
- 12.1.11 EUROAPI
- 12.1.11.1 Business overview
- 12.1.11.2 Services offered
- 12.1.11.3 Recent developments
- 12.1.11.3.1 Deals
- 12.1.11.3.2 Expansions
- 12.1.12 AJINOMOTO CO., INC.
- 12.1.12.1 Business overview
- 12.1.12.2 Services offered
- 12.1.13 ST PHARM
- 12.1.13.1 Business overview
- 12.1.13.2 Services offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Expansions
- 12.1.13.3.2 Other developments
- 12.1.14 KANEKA CORPORATION
- 12.1.14.1 Business overview
- 12.1.14.2 Services offered
- 12.1.15 POLYPEPTIDE GROUP
- 12.1.15.1 Business overview
- 12.1.15.2 Services offered
- 12.1.15.3 Recent developments
- 12.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
- 12.1.16.1 Business overview
- 12.1.16.2 Services offered
- 12.1.17 BIOSPRING
- 12.1.17.1 Business overview
- 12.1.17.2 Services offered
- 12.1.17.3 Recent developments
- 12.1.17.3.1 Service approvals
- 12.1.17.3.2 Expansions
- 12.2 OTHER PLAYERS
- 12.2.1 OLIGO FACTORY
- 12.2.2 CORDEN PHARMA
- 12.2.3 LGC BIOSEARCH TECHNOLOGIES
- 12.2.4 BI0-SYNTHESIS, INC.
- 12.2.5 MICROSYNTH
- 12.2.6 SYNOLIGO BIOTECHNOLOGIES, INC.
- 12.2.7 HONGENE BIOTECH CORPORATION
- 12.2.8 SYLENTIS, S.A.
- 12.2.9 CREATIVE BIOGENE
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
